MAIA Biotechnology Inc

MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. Its product, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded on August 3, 2018 and is headquartered in Chicago, IL.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CHICAGO--( BUSINESS WIRE )--MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA,” “the Company”), announced today that regulatory authorities in three European countries, Hungary, Poland, and Bulgaria, have approved the implementation of THIO-101, MAIA's Phase 2 clinical trial evaluating its lead therapeutic candidate, THIO, in patients with Non-Small Cell Lung Cancer (NSCLC). The first patients in THIO-101 were dosed in Australia earlier this year.

MAIA Biotechnology Expands Phase 2 THIO-101 Trial to Europe

CHICAGO--( BUSINESS WIRE )--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs, announced today that certain officers and directors of the Company, including Founder and Chief Executive Officer Vlad Vitoc, M.D., and leading investor and Board Member Stan Smith, Ph.D., plan to initiate additional investing in the Company's common stock. These investments will be entered into as pre-arranged trading plans in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The Rule 10b5-1 trading plans will permit the insiders to purchase shares of the Company's common stock over a specific period of time, at times that these insiders might otherwise be precluded from doing so under insider trading laws or other trading restrictions, such as the Company's insider trading policy. The Rule 10b5-1 trading plans will be administered by an independent broker. The amount, timing and prices of the purchases will vary based on market conditions and other factors, as well as being subject to the present parameters set forth in the plans.

MAIA Biotechnology Announces Establishment of Rule 10b5-1 Trading Plan

CHICAGO--( BUSINESS WIRE )--MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA,” “the Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the results of a pre-clinical study of the Company's lead drug candidate, THIO, in hepatocellular carcinoma (HCC) in vitro and in vivo models. MAIA presented the data at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting, held Nov. 8-12 virtually and in Boston.

MAIA Biotechnology Presents Preclinical Data at SITC Annual Meeting Validating Efficacy of THIO in Treating Hepatocellular Carcinoma

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today reported financial results for the third quarter ended September 30, 2022, and provided a corporate update.

MAIA Biotechnology Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Chicago, Illinois--(Newsfile Corp. - October 12, 2022) - MAIA Biotechnology (NYSE: MAIA), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs, will be participating in The ThinkEquity Conference, which will take place on October 26, 2022 at The Mandarin Oriental Hotel in New York. Vlad Vitoc will be presenting at 3:00 PM ET on October 26th. Interested parties can register to attend here.

MAIA Biotechnology: Invitation to The ThinkEquity Conference

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs, announced today that the management team will participate in the ThinkEquity Conference. The MAIA team is scheduled to present on Wednesday, October 26th at 3:00 pm ET and will host investor meetings at the Conference. A webcast of the presentation will be available on the News & Events p

MAIA Biotechnology to Participate in ThinkEquity Conference

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs, announced today that it will present the results of a study of the anticancer agent 6-thio-dG (THIO) in hepatocellular carcinoma (HCC) in vitro and in vivo models at the EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics. The symposium is taking place Oct. 26-28, 2022

MAIA Biotechnology to Present at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs, announced today that the management team will participate in the H.C. Wainwright 24th Annual Global Investment Conference that will be held September 12th – 14th. The MAIA team is scheduled to present on September 12th at 7:00 am ET and will host investor meetings at the Conference through Se

MAIA Biotechnology to Participate in H.C. Wainwright 24th Annual Global Investment Conference

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA,” “the Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it will present the design of its ongoing THIO-101 trial at the European Society for Medical Oncology (ESMO) Congress 2022, being held from September 9th to 13th in Paris, France. THIO is a telomere-targeting agent currently in clinical development to evaluate its activity in non-small ce

MAIA Biotechnology to Present Design of THIO-101 Trial at European Society for Medical Oncology (ESMO) Congress 2022

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs (“MAIA”), today announced that it has been selected to conduct an oral presentation covering the novel THIO platform at the XIV International Round Table on Nucleosides, Nucleotides, and Nucleic Acids, which will be taking place in Stockholm, Sweden on August 28 – 31, 2022. This scientific exchange presentation will summarize an unexpected

MAIA Biotechnology to Present Anticancer THIO Platform at XIV International Round Table on Nucleosides, Nucleotides, and Nucleic Acids

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today reported financial results for the second quarter ended June 30, 2022, and provided a corporate update. “We continue to make significant progress with advancing the clinical development of THIO. We recently dosed the first patient in our Phase 2 clinical trial for NSCLC, THIO-101, for Non-Small Cell Lu

MAIA Biotechnology Reports Second Quarter 2022 Financial Results and Provides Corporate Update

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to THIO, a telomere-targeting agent currently in development to evaluate its activity in multiple cancer indications, for the treatment of small-cell lung cancer (SCLC). This is the seco

MAIA Biotechnology Receives FDA Orphan Drug Designation for THIO for the Treatment of Small-Cell Lung Cancer (SCLC)

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the closing of its initial public offering of 2,000,000 shares of the Company's common stock at a public offering price of $5.00 per share. The gross proceeds from the initial public offering were $10,000,000 prior to deducting underwriting discounts, commissions, and other offering expenses.

MAIA Biotechnology Announces Closing of Initial Public Offering

MAIA Biotechnology (NYSE: MAIA ), which began trading on Thursday following its initial public offering, is climbing sharply this morning. In mid-morning trading, MAIA stock jumped 15% to $6.66.

Why Is MAIA Biotechnology (MAIA) Stock Soaring 15% Higher Today?

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the pricing of its initial public offering of 2,000,000 shares of the Company's common stock at a public offering price of $5.00 per share for aggregate gross proceeds of $10,000,000 prior to deducting underwriting discounts, commissions, and other offering expenses. In addition, the Company

MAIA Biotechnology Announces Pricing of Initial Public Offering

News for MAIA Biotechnology Inc Stock (MAIA)